nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—ABCB1—Lisinopril—systemic scleroderma	0.123	0.218	CbGbCtD
Rivaroxaban—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.111	0.197	CbGbCtD
Rivaroxaban—ABCB1—Captopril—systemic scleroderma	0.0919	0.163	CbGbCtD
Rivaroxaban—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0724	0.129	CbGbCtD
Rivaroxaban—ABCB1—Prednisone—systemic scleroderma	0.0579	0.103	CbGbCtD
Rivaroxaban—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0434	0.077	CbGbCtD
Rivaroxaban—CYP3A4—Prednisone—systemic scleroderma	0.0347	0.0616	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—systemic scleroderma	0.029	0.0515	CbGbCtD
Rivaroxaban—CYP2J2—artery—systemic scleroderma	0.00782	0.264	CbGeAlD
Rivaroxaban—CYP2J2—blood vessel—systemic scleroderma	0.00609	0.206	CbGeAlD
Rivaroxaban—CYP2J2—skin of body—systemic scleroderma	0.00282	0.0951	CbGeAlD
Rivaroxaban—F10—tendon—systemic scleroderma	0.00262	0.0884	CbGeAlD
Rivaroxaban—F10—lung—systemic scleroderma	0.0023	0.0775	CbGeAlD
Rivaroxaban—CYP2J2—tendon—systemic scleroderma	0.00215	0.0724	CbGeAlD
Rivaroxaban—CYP2J2—lung—systemic scleroderma	0.00189	0.0636	CbGeAlD
Rivaroxaban—ABCB1—blood vessel—systemic scleroderma	0.00114	0.0384	CbGeAlD
Rivaroxaban—CYP3A5—digestive system—systemic scleroderma	0.000794	0.0268	CbGeAlD
Rivaroxaban—CYP3A5—lung—systemic scleroderma	0.000663	0.0224	CbGeAlD
Rivaroxaban—CYP3A4—digestive system—systemic scleroderma	0.000596	0.0201	CbGeAlD
Rivaroxaban—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000596	0.00146	CcSEcCtD
Rivaroxaban—Discomfort—Mycophenolic acid—systemic scleroderma	0.000596	0.00146	CcSEcCtD
Rivaroxaban—Nervous system disorder—Leflunomide—systemic scleroderma	0.000594	0.00146	CcSEcCtD
Rivaroxaban—Pruritus—Mometasone—systemic scleroderma	0.000592	0.00145	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Lisinopril—systemic scleroderma	0.000592	0.00145	CcSEcCtD
Rivaroxaban—Tachycardia—Leflunomide—systemic scleroderma	0.000591	0.00145	CcSEcCtD
Rivaroxaban—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00059	0.00145	CcSEcCtD
Rivaroxaban—Anaemia—Lisinopril—systemic scleroderma	0.000589	0.00145	CcSEcCtD
Rivaroxaban—Skin disorder—Leflunomide—systemic scleroderma	0.000588	0.00145	CcSEcCtD
Rivaroxaban—Angioedema—Lisinopril—systemic scleroderma	0.000583	0.00143	CcSEcCtD
Rivaroxaban—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000582	0.00143	CcSEcCtD
Rivaroxaban—Abdominal pain—Captopril—systemic scleroderma	0.000581	0.00143	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000579	0.00142	CcSEcCtD
Rivaroxaban—Oedema—Mycophenolic acid—systemic scleroderma	0.000578	0.00142	CcSEcCtD
Rivaroxaban—Nausea—Pentoxifylline—systemic scleroderma	0.000576	0.00141	CcSEcCtD
Rivaroxaban—Malaise—Lisinopril—systemic scleroderma	0.000575	0.00141	CcSEcCtD
Rivaroxaban—Infection—Mycophenolic acid—systemic scleroderma	0.000574	0.00141	CcSEcCtD
Rivaroxaban—Diarrhoea—Mometasone—systemic scleroderma	0.000573	0.00141	CcSEcCtD
Rivaroxaban—Syncope—Lisinopril—systemic scleroderma	0.000572	0.0014	CcSEcCtD
Rivaroxaban—Renal failure acute—Methotrexate—systemic scleroderma	0.000569	0.0014	CcSEcCtD
Rivaroxaban—Shock—Mycophenolic acid—systemic scleroderma	0.000569	0.0014	CcSEcCtD
Rivaroxaban—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000567	0.00139	CcSEcCtD
Rivaroxaban—Hypotension—Leflunomide—systemic scleroderma	0.000566	0.00139	CcSEcCtD
Rivaroxaban—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000564	0.00139	CcSEcCtD
Rivaroxaban—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000561	0.00138	CcSEcCtD
Rivaroxaban—Loss of consciousness—Lisinopril—systemic scleroderma	0.000561	0.00138	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000554	0.00136	CcSEcCtD
Rivaroxaban—Chest pain—Lisinopril—systemic scleroderma	0.000543	0.00133	CcSEcCtD
Rivaroxaban—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000541	0.00133	CcSEcCtD
Rivaroxaban—Dyspnoea—Leflunomide—systemic scleroderma	0.00054	0.00133	CcSEcCtD
Rivaroxaban—Hypotension—Mycophenolic acid—systemic scleroderma	0.00054	0.00133	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000539	0.00132	CcSEcCtD
Rivaroxaban—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000537	0.00132	CcSEcCtD
Rivaroxaban—Discomfort—Lisinopril—systemic scleroderma	0.000536	0.00132	CcSEcCtD
Rivaroxaban—Dyspepsia—Leflunomide—systemic scleroderma	0.000533	0.00131	CcSEcCtD
Rivaroxaban—Vomiting—Mometasone—systemic scleroderma	0.000532	0.00131	CcSEcCtD
Rivaroxaban—Dry mouth—Lisinopril—systemic scleroderma	0.000531	0.0013	CcSEcCtD
Rivaroxaban—Feeling abnormal—Azathioprine—systemic scleroderma	0.000529	0.0013	CcSEcCtD
Rivaroxaban—Rash—Mometasone—systemic scleroderma	0.000528	0.0013	CcSEcCtD
Rivaroxaban—Asthenia—Captopril—systemic scleroderma	0.000527	0.0013	CcSEcCtD
Rivaroxaban—Dermatitis—Mometasone—systemic scleroderma	0.000527	0.00129	CcSEcCtD
Rivaroxaban—Osteoarthritis—Methotrexate—systemic scleroderma	0.000526	0.00129	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000525	0.00129	CcSEcCtD
Rivaroxaban—Headache—Mometasone—systemic scleroderma	0.000524	0.00129	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000523	0.00128	CcSEcCtD
Rivaroxaban—Fatigue—Leflunomide—systemic scleroderma	0.000522	0.00128	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00052	0.00128	CcSEcCtD
Rivaroxaban—Oedema—Lisinopril—systemic scleroderma	0.00052	0.00128	CcSEcCtD
Rivaroxaban—Pruritus—Captopril—systemic scleroderma	0.00052	0.00128	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000518	0.00127	CcSEcCtD
Rivaroxaban—Pain—Leflunomide—systemic scleroderma	0.000518	0.00127	CcSEcCtD
Rivaroxaban—Constipation—Leflunomide—systemic scleroderma	0.000518	0.00127	CcSEcCtD
Rivaroxaban—Infection—Lisinopril—systemic scleroderma	0.000517	0.00127	CcSEcCtD
Rivaroxaban—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000516	0.00127	CcSEcCtD
Rivaroxaban—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000515	0.00127	CcSEcCtD
Rivaroxaban—Shock—Lisinopril—systemic scleroderma	0.000512	0.00126	CcSEcCtD
Rivaroxaban—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000511	0.00125	CcSEcCtD
Rivaroxaban—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000509	0.00125	CcSEcCtD
Rivaroxaban—Tachycardia—Lisinopril—systemic scleroderma	0.000508	0.00125	CcSEcCtD
Rivaroxaban—Abdominal pain—Azathioprine—systemic scleroderma	0.000507	0.00125	CcSEcCtD
Rivaroxaban—Skin disorder—Lisinopril—systemic scleroderma	0.000506	0.00124	CcSEcCtD
Rivaroxaban—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000504	0.00124	CcSEcCtD
Rivaroxaban—Diarrhoea—Captopril—systemic scleroderma	0.000503	0.00124	CcSEcCtD
Rivaroxaban—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000501	0.00123	CcSEcCtD
Rivaroxaban—Feeling abnormal—Leflunomide—systemic scleroderma	0.000499	0.00123	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000499	0.00123	CcSEcCtD
Rivaroxaban—Fatigue—Mycophenolic acid—systemic scleroderma	0.000498	0.00122	CcSEcCtD
Rivaroxaban—Nausea—Mometasone—systemic scleroderma	0.000497	0.00122	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000495	0.00122	CcSEcCtD
Rivaroxaban—Pain—Mycophenolic acid—systemic scleroderma	0.000494	0.00121	CcSEcCtD
Rivaroxaban—Constipation—Mycophenolic acid—systemic scleroderma	0.000494	0.00121	CcSEcCtD
Rivaroxaban—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000491	0.00121	CcSEcCtD
Rivaroxaban—Hypotension—Lisinopril—systemic scleroderma	0.000486	0.00119	CcSEcCtD
Rivaroxaban—Dizziness—Captopril—systemic scleroderma	0.000486	0.00119	CcSEcCtD
Rivaroxaban—Urticaria—Leflunomide—systemic scleroderma	0.000481	0.00118	CcSEcCtD
Rivaroxaban—Abdominal pain—Leflunomide—systemic scleroderma	0.000479	0.00118	CcSEcCtD
Rivaroxaban—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000476	0.00117	CcSEcCtD
Rivaroxaban—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000476	0.00117	CcSEcCtD
Rivaroxaban—Hypersensitivity—Azathioprine—systemic scleroderma	0.000473	0.00116	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000473	0.00116	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000472	0.00116	CcSEcCtD
Rivaroxaban—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00047	0.00115	CcSEcCtD
Rivaroxaban—Vomiting—Captopril—systemic scleroderma	0.000467	0.00115	CcSEcCtD
Rivaroxaban—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000465	0.00114	CcSEcCtD
Rivaroxaban—Dyspnoea—Lisinopril—systemic scleroderma	0.000464	0.00114	CcSEcCtD
Rivaroxaban—Rash—Captopril—systemic scleroderma	0.000463	0.00114	CcSEcCtD
Rivaroxaban—Dermatitis—Captopril—systemic scleroderma	0.000463	0.00114	CcSEcCtD
Rivaroxaban—Headache—Captopril—systemic scleroderma	0.00046	0.00113	CcSEcCtD
Rivaroxaban—Dyspepsia—Lisinopril—systemic scleroderma	0.000458	0.00113	CcSEcCtD
Rivaroxaban—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000457	0.00112	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00112	CcSEcCtD
Rivaroxaban—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00112	CcSEcCtD
Rivaroxaban—Infection—Mycophenolate mofetil—systemic scleroderma	0.000453	0.00111	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000449	0.0011	CcSEcCtD
Rivaroxaban—Fatigue—Lisinopril—systemic scleroderma	0.000449	0.0011	CcSEcCtD
Rivaroxaban—Shock—Mycophenolate mofetil—systemic scleroderma	0.000449	0.0011	CcSEcCtD
Rivaroxaban—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000447	0.0011	CcSEcCtD
Rivaroxaban—Hypersensitivity—Leflunomide—systemic scleroderma	0.000446	0.0011	CcSEcCtD
Rivaroxaban—Pain—Lisinopril—systemic scleroderma	0.000445	0.00109	CcSEcCtD
Rivaroxaban—Constipation—Lisinopril—systemic scleroderma	0.000445	0.00109	CcSEcCtD
Rivaroxaban—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000445	0.00109	CcSEcCtD
Rivaroxaban—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000443	0.00109	CcSEcCtD
Rivaroxaban—Diarrhoea—Azathioprine—systemic scleroderma	0.000439	0.00108	CcSEcCtD
Rivaroxaban—Haemoglobin—Prednisone—systemic scleroderma	0.000437	0.00107	CcSEcCtD
Rivaroxaban—Nausea—Captopril—systemic scleroderma	0.000437	0.00107	CcSEcCtD
Rivaroxaban—Haemorrhage—Prednisone—systemic scleroderma	0.000435	0.00107	CcSEcCtD
Rivaroxaban—Asthenia—Leflunomide—systemic scleroderma	0.000435	0.00107	CcSEcCtD
Rivaroxaban—Feeling abnormal—Lisinopril—systemic scleroderma	0.000429	0.00105	CcSEcCtD
Rivaroxaban—Pruritus—Leflunomide—systemic scleroderma	0.000429	0.00105	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Prednisone—systemic scleroderma	0.000428	0.00105	CcSEcCtD
Rivaroxaban—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000426	0.00105	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000426	0.00105	CcSEcCtD
Rivaroxaban—Dizziness—Azathioprine—systemic scleroderma	0.000424	0.00104	CcSEcCtD
Rivaroxaban—ABCB1—digestive system—systemic scleroderma	0.000422	0.0142	CbGeAlD
Rivaroxaban—Asthenia—Mycophenolic acid—systemic scleroderma	0.000415	0.00102	CcSEcCtD
Rivaroxaban—Diarrhoea—Leflunomide—systemic scleroderma	0.000414	0.00102	CcSEcCtD
Rivaroxaban—Urticaria—Lisinopril—systemic scleroderma	0.000413	0.00102	CcSEcCtD
Rivaroxaban—Abdominal pain—Lisinopril—systemic scleroderma	0.000411	0.00101	CcSEcCtD
Rivaroxaban—Pruritus—Mycophenolic acid—systemic scleroderma	0.000409	0.001	CcSEcCtD
Rivaroxaban—Vomiting—Azathioprine—systemic scleroderma	0.000408	0.001	CcSEcCtD
Rivaroxaban—Eye disorder—Prednisone—systemic scleroderma	0.000407	0.000999	CcSEcCtD
Rivaroxaban—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000999	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—systemic scleroderma	0.000405	0.000995	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—systemic scleroderma	0.000405	0.000995	CcSEcCtD
Rivaroxaban—Rash—Azathioprine—systemic scleroderma	0.000404	0.000993	CcSEcCtD
Rivaroxaban—Dermatitis—Azathioprine—systemic scleroderma	0.000404	0.000993	CcSEcCtD
Rivaroxaban—Headache—Azathioprine—systemic scleroderma	0.000402	0.000987	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000402	0.000986	CcSEcCtD
Rivaroxaban—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000401	0.000986	CcSEcCtD
Rivaroxaban—Dizziness—Leflunomide—systemic scleroderma	0.000401	0.000984	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—systemic scleroderma	0.000398	0.000978	CcSEcCtD
Rivaroxaban—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000395	0.000971	CcSEcCtD
Rivaroxaban—Angiopathy—Prednisone—systemic scleroderma	0.000395	0.00097	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000394	0.000967	CcSEcCtD
Rivaroxaban—Immune system disorder—Prednisone—systemic scleroderma	0.000393	0.000965	CcSEcCtD
Rivaroxaban—Pain—Mycophenolate mofetil—systemic scleroderma	0.00039	0.000958	CcSEcCtD
Rivaroxaban—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00039	0.000958	CcSEcCtD
Rivaroxaban—Haematuria—Methotrexate—systemic scleroderma	0.000386	0.000949	CcSEcCtD
Rivaroxaban—Vomiting—Leflunomide—systemic scleroderma	0.000385	0.000946	CcSEcCtD
Rivaroxaban—Hypersensitivity—Lisinopril—systemic scleroderma	0.000383	0.000942	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000383	0.000941	CcSEcCtD
Rivaroxaban—Dizziness—Mycophenolic acid—systemic scleroderma	0.000382	0.000939	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—systemic scleroderma	0.000382	0.000938	CcSEcCtD
Rivaroxaban—Rash—Leflunomide—systemic scleroderma	0.000382	0.000938	CcSEcCtD
Rivaroxaban—Dermatitis—Leflunomide—systemic scleroderma	0.000382	0.000937	CcSEcCtD
Rivaroxaban—Nausea—Azathioprine—systemic scleroderma	0.000381	0.000936	CcSEcCtD
Rivaroxaban—Headache—Leflunomide—systemic scleroderma	0.000379	0.000932	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—systemic scleroderma	0.000378	0.000929	CcSEcCtD
Rivaroxaban—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000923	CcSEcCtD
Rivaroxaban—Asthenia—Lisinopril—systemic scleroderma	0.000373	0.000917	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000373	0.000916	CcSEcCtD
Rivaroxaban—Pruritus—Lisinopril—systemic scleroderma	0.000368	0.000905	CcSEcCtD
Rivaroxaban—Vomiting—Mycophenolic acid—systemic scleroderma	0.000367	0.000903	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—systemic scleroderma	0.000365	0.000898	CcSEcCtD
Rivaroxaban—Rash—Mycophenolic acid—systemic scleroderma	0.000364	0.000895	CcSEcCtD
Rivaroxaban—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000364	0.000894	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—systemic scleroderma	0.000364	0.000893	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—systemic scleroderma	0.000364	0.000893	CcSEcCtD
Rivaroxaban—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000362	0.00089	CcSEcCtD
Rivaroxaban—Headache—Mycophenolic acid—systemic scleroderma	0.000362	0.000889	CcSEcCtD
Rivaroxaban—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000361	0.000886	CcSEcCtD
Rivaroxaban—Nausea—Leflunomide—systemic scleroderma	0.00036	0.000884	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000359	0.000882	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—systemic scleroderma	0.000356	0.000876	CcSEcCtD
Rivaroxaban—Diarrhoea—Lisinopril—systemic scleroderma	0.000356	0.000875	CcSEcCtD
Rivaroxaban—ABCB1—lung—systemic scleroderma	0.000352	0.0119	CbGeAlD
Rivaroxaban—Ill-defined disorder—Prednisone—systemic scleroderma	0.000351	0.000863	CcSEcCtD
Rivaroxaban—Anaemia—Prednisone—systemic scleroderma	0.00035	0.00086	CcSEcCtD
Rivaroxaban—Angioedema—Prednisone—systemic scleroderma	0.000346	0.00085	CcSEcCtD
Rivaroxaban—Dizziness—Lisinopril—systemic scleroderma	0.000344	0.000845	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—systemic scleroderma	0.000344	0.000845	CcSEcCtD
Rivaroxaban—Nausea—Mycophenolic acid—systemic scleroderma	0.000343	0.000843	CcSEcCtD
Rivaroxaban—Malaise—Prednisone—systemic scleroderma	0.000342	0.000839	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—systemic scleroderma	0.00034	0.000835	CcSEcCtD
Rivaroxaban—Syncope—Prednisone—systemic scleroderma	0.00034	0.000834	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—systemic scleroderma	0.000337	0.000829	CcSEcCtD
Rivaroxaban—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000825	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisone—systemic scleroderma	0.000333	0.000818	CcSEcCtD
Rivaroxaban—Vomiting—Lisinopril—systemic scleroderma	0.000331	0.000813	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—systemic scleroderma	0.00033	0.00081	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—systemic scleroderma	0.000328	0.000807	CcSEcCtD
Rivaroxaban—Rash—Lisinopril—systemic scleroderma	0.000328	0.000806	CcSEcCtD
Rivaroxaban—Dermatitis—Lisinopril—systemic scleroderma	0.000328	0.000805	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000328	0.000805	CcSEcCtD
Rivaroxaban—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000327	0.000804	CcSEcCtD
Rivaroxaban—Headache—Lisinopril—systemic scleroderma	0.000326	0.000801	CcSEcCtD
Rivaroxaban—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000323	0.000793	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00032	0.000787	CcSEcCtD
Rivaroxaban—Discomfort—Prednisone—systemic scleroderma	0.000319	0.000783	CcSEcCtD
Rivaroxaban—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000312	0.000766	CcSEcCtD
Rivaroxaban—Nausea—Lisinopril—systemic scleroderma	0.000309	0.000759	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisone—systemic scleroderma	0.000309	0.000759	CcSEcCtD
Rivaroxaban—Oedema—Prednisone—systemic scleroderma	0.000309	0.000759	CcSEcCtD
Rivaroxaban—Infection—Prednisone—systemic scleroderma	0.000307	0.000754	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—systemic scleroderma	0.000306	0.000752	CcSEcCtD
Rivaroxaban—Shock—Prednisone—systemic scleroderma	0.000304	0.000747	CcSEcCtD
Rivaroxaban—Nervous system disorder—Prednisone—systemic scleroderma	0.000303	0.000745	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisone—systemic scleroderma	0.000302	0.000741	CcSEcCtD
Rivaroxaban—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000302	0.000741	CcSEcCtD
Rivaroxaban—Skin disorder—Prednisone—systemic scleroderma	0.0003	0.000738	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000294	0.000721	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—systemic scleroderma	0.000293	0.000719	CcSEcCtD
Rivaroxaban—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000712	CcSEcCtD
Rivaroxaban—Rash—Mycophenolate mofetil—systemic scleroderma	0.000288	0.000706	CcSEcCtD
Rivaroxaban—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000287	0.000706	CcSEcCtD
Rivaroxaban—Headache—Mycophenolate mofetil—systemic scleroderma	0.000286	0.000702	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—systemic scleroderma	0.000285	0.000701	CcSEcCtD
Rivaroxaban—Dyspepsia—Prednisone—systemic scleroderma	0.000272	0.000668	CcSEcCtD
Rivaroxaban—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000665	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—systemic scleroderma	0.000269	0.000662	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000268	0.000657	CcSEcCtD
Rivaroxaban—Fatigue—Prednisone—systemic scleroderma	0.000267	0.000655	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—systemic scleroderma	0.000266	0.000654	CcSEcCtD
Rivaroxaban—Constipation—Prednisone—systemic scleroderma	0.000264	0.000649	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000258	0.000635	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—systemic scleroderma	0.000257	0.00063	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisone—systemic scleroderma	0.000255	0.000626	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—systemic scleroderma	0.000253	0.000622	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000253	0.000621	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—systemic scleroderma	0.000251	0.000616	CcSEcCtD
Rivaroxaban—Urticaria—Prednisone—systemic scleroderma	0.000246	0.000603	CcSEcCtD
Rivaroxaban—Abdominal pain—Prednisone—systemic scleroderma	0.000244	0.0006	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—systemic scleroderma	0.000241	0.000593	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—systemic scleroderma	0.00023	0.000566	CcSEcCtD
Rivaroxaban—Hypersensitivity—Prednisone—systemic scleroderma	0.000228	0.000559	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—systemic scleroderma	0.000227	0.000559	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000223	0.000548	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—systemic scleroderma	0.000223	0.000547	CcSEcCtD
Rivaroxaban—Asthenia—Prednisone—systemic scleroderma	0.000222	0.000545	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—systemic scleroderma	0.000221	0.000543	CcSEcCtD
Rivaroxaban—Pruritus—Prednisone—systemic scleroderma	0.000219	0.000537	CcSEcCtD
Rivaroxaban—Feeling abnormal—Methotrexate—systemic scleroderma	0.000213	0.000523	CcSEcCtD
Rivaroxaban—Diarrhoea—Prednisone—systemic scleroderma	0.000212	0.00052	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000211	0.000519	CcSEcCtD
Rivaroxaban—Urticaria—Methotrexate—systemic scleroderma	0.000205	0.000504	CcSEcCtD
Rivaroxaban—Dizziness—Prednisone—systemic scleroderma	0.000204	0.000502	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—systemic scleroderma	0.000204	0.000502	CcSEcCtD
Rivaroxaban—Vomiting—Prednisone—systemic scleroderma	0.000197	0.000483	CcSEcCtD
Rivaroxaban—Rash—Prednisone—systemic scleroderma	0.000195	0.000479	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisone—systemic scleroderma	0.000195	0.000478	CcSEcCtD
Rivaroxaban—Headache—Prednisone—systemic scleroderma	0.000194	0.000476	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—systemic scleroderma	0.00019	0.000468	CcSEcCtD
Rivaroxaban—Asthenia—Methotrexate—systemic scleroderma	0.000185	0.000455	CcSEcCtD
Rivaroxaban—Nausea—Prednisone—systemic scleroderma	0.000184	0.000451	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—systemic scleroderma	0.000183	0.000449	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—systemic scleroderma	0.000177	0.000434	CcSEcCtD
Rivaroxaban—Dizziness—Methotrexate—systemic scleroderma	0.000171	0.00042	CcSEcCtD
Rivaroxaban—Vomiting—Methotrexate—systemic scleroderma	0.000164	0.000403	CcSEcCtD
Rivaroxaban—Rash—Methotrexate—systemic scleroderma	0.000163	0.0004	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—systemic scleroderma	0.000163	0.0004	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—systemic scleroderma	0.000162	0.000398	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—systemic scleroderma	0.000153	0.000377	CcSEcCtD
